GSK press releases
Follow
GSK provides update on US FDA advisory committee review of Blenrep (belantamab mafodotin-blmf) combinations for patients with relapsed/refractory multiple myeloma
The US FDA Oncologic Drugs Advisory Committee voted against the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations.
